Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Study Determines Onglyza Ineffective at Reducing Heart Attack, Stroke Risks for Diabetics

Filed June 21st, 2013 Joshua Sophy

A new study shows that the type 2 diabetes drug Onglyza does not reduce the chance a person will suffer a heart attack or be stricken with heart disease.

According to a report at 4-traders.com, the new study examined the heart risks associated with Onglyza. The study found that the drug did not increase the risk of heart attacks or heart disease, the number-one killer of diabetics, but it did not work at reducing those risks, either.

Onglyza is in a class of drugs known as DPP-4 inhibitors. Another popular diabetes drug in this class is Januvia. According to our previous reports, Januvia has been linked to an increased risk of pancreatic cancer. And, as a whole, drugs used to treat type 2 diabetes have come under increased scrutiny because of their numerous health risks.

We’ve reported on other diabetes drugs, like Avandia, Actos, and Januvia. Avandia has been strictly limited from the market and is now the ultimate in last resorts for diabetics when all other drugs fail. Concerns continue to grow over the safety of Actos because of its link to life-threatening bladder cancer.

This most recent study did not examine the risks of pancreatic cancer associated with Onglyza, according to the 4-traders.com report, instead focusing on the heart risks that could be linked to it. Though full details of the study are not yet available, the summary shows that Onglyza did not reduce the risk of heart attack, stroke, or heart disease, the main reason it is prescribed.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!